Edition:
United Kingdom

Shanghai Fosun Pharmaceutical Group Co Ltd (2196.HK)

2196.HK on Hong Kong Stock

23.00HKD
17 Sep 2019
Change (% chg)

HK$-0.40 (-1.71%)
Prev Close
HK$23.40
Open
HK$23.20
Day's High
HK$23.40
Day's Low
HK$22.85
Volume
3,366,259
Avg. Vol
3,118,708
52-wk High
HK$31.50
52-wk Low
HK$19.76

Latest Key Developments (Source: Significant Developments)

Shanghai Fosun Pharmaceutical's H1 Net Profit Down 2.8% Y/Y
Monday, 26 Aug 2019 

Aug 26 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>2196.HK ::SAYS H1 NET PROFIT DOWN 2.8% Y/Y.  Full Article

Shanghai Fosun Pharmaceutical Group To Establish JV
Monday, 26 Aug 2019 

Aug 26 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>::SHANGHAI FOSUN PHARMACEUTICAL GROUP - COMPANY AND SFHIH ENTERED INTO INVESTMENT AGREEMENT IN RELATION TO PROPOSED ESTABLISHMENT OF JV CO.SHANGHAI FOSUN PHARMACEUTICAL GROUP -REGISTERED CAPITAL OF JV COMPANY IS RMB10 MILLION, OF WHICH CO TO MAKE CONTRIBUTION IN AMOUNT OF RMB6 MILLION.  Full Article

Shanghai Fosun Pharma To Sell Healthy Harmony For About $523.15 Million
Tuesday, 30 Jul 2019 

July 30 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>2196.HK::SAYS NF UNICORN ACQUISITION L.P. AND NEW FRONTIER CORP AGREE TO BUY HEALTHY HARMONY HOLDINGS L.P. AND HEALTHY HARMONY GP INC FOR ABOUT $523.15 MILLION.SAYS IT EXPECTS TO GAIN 1.65 BILLION YUAN ($239.80 million) FROM THE DEAL, PROCEEDS WILL BE USED TO BOOST WORKING CAPITAL, REPAY DEBTS.  Full Article

Shanghai Fosun Pharma's Unit To Buy GlaxoSmithkline Pharmaceuticals (Suzhou)
Monday, 8 Jul 2019 

July 8 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>2196.HK::SAYS UNIT SIGNS AGREEMENT TO BUY GLAXOSMITHKLINE PHARMACEUTICALS (SUZHOU) FOR UP TO 250.0 MILLION YUAN ($36.34 million).  Full Article

Shanghai Fosun Pharmaceutical Says Unit Gets Certificate Of Drug Registration Approval By NMPA
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>::SHANGHAI FOSUN PHARMACEUTICAL GROUP-SHANGHAI HENLIUS BIOPHARMACEUTICAL GETS CERTIFICATE OF DRUG REGISTRATION APPROVAL FOR NEW DRUG ISSUED BY NMPA.  Full Article

Shanghai Fosun Pharma's JV Shanghai Henlius Biotech Submits Hong Kong IPO Application To Exchange
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>2196.HK::SAYS ITS JV SHANGHAI HENLIUS BIOTECH INC HAS SUBMITTED ITS H-SHARES INITIAL PUBIC OFFERING APPLICATION TO HONG KONG STOCK EXCHANGE ON DEC 13.  Full Article

Fosun International Updates On Proposed Spin-Off Of Shanghai Henlius
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Fosun International Ltd <0656.HK>::FOSUN PHARMA AND CO MADE JOINT APPLICATION TO HONG KONG STOCK EXCHANGE FOR APPROVAL OF PROPOSED SPIN-OFF OF SHANGHAI HENLIUS.  Full Article

Revance Announces China Market License Agreement With Fosun Pharma For RT002
Tuesday, 4 Dec 2018 

Dec 4 (Reuters) - Revance Therapeutics Inc ::REVANCE ANNOUNCES CHINA MARKET LICENSE AGREEMENT WITH FOSUN PHARMA FOR RT002.REVANCE THERAPEUTICS INC - UPFRONT PAYMENT OF $30 MILLION, PLUS POTENTIAL MILESTONE PAYMENT AND TIERED ROYALTIES ON FUTURE SALES.REVANCE THERAPEUTICS INC - REVANCE ELIGIBLE TO RECEIVE ADDITIONAL POTENTIAL DEVELOPMENT AND SALES MILESTONE PAYMENTS OF UP TO $230.5 MILLION.REVANCE THERAPEUTICS INC - NO TRANSFER OF INTELLECTUAL PROPERTY..REVANCE THERAPEUTICS INC - REVANCE ELIGIBLE TO RECEIVE TIERED LOW-DOUBLE-DIGIT TO HIGH-TEEN ROYALTY PAYMENTS ON FUTURE NET SALES FROM DEAL.REVANCE THERAPEUTICS INC - FOSUN PHARMA WILL BE RESPONSIBLE FOR CONDUCTING NECESSARY CLINICAL STUDIES, MARKETING AND SALES IN TERRITORY.REVANCE THERAPEUTICS - FOSUN HAS EXCLUSIVE RIGHTS TO DEVELOP, COMMERCIALIZE DAXIBOTULINUMTOXINA FOR INJECTION IN MAINLAND CHINA, HONG KONG AND MACAU.  Full Article

Shanghai Fosun Pharmaceutical Says 9-Month Net Profit Down 13.4 Percent Y/Y
Monday, 29 Oct 2018 

Oct 29 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>2196.HK::SAYS 9-MONTH NET PROFIT DOWN 13.4 PERCENT Y/Y.  Full Article

Diamedica Therapeutics And Ahon Pharma Announce Signing Of License Agreement For Dm199 In China
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - DiaMedica Therapeutics Inc ::DIAMEDICA THERAPEUTICS AND AHON PHARMA, A FOSUN PHARMA PORTFOLIO COMPANY, ANNOUNCES SIGNING OF LICENSE AGREEMENT FOR DM199 IN CHINA FOR ACUTE ISCHEMIC STROKE.DIAMEDICA -AGREEMENT ALLOWS AHON TO HAVE EXCLUSIVE RIGHTS TO DEVELOP & COMMERCIALIZE DM199 IN MAINLAND CHINA, TAIWAN, HONG KONG S.A.R. AND MACAU S.A.R.DIAMEDICA THERAPEUTICS - UNDER TERMS OF AGREEMENT, CO IS ENTITLED TO RECEIVE AN UPFRONT PAYMENT OF $5 MILLION, UPON CLEARANCE TO INITIATE CLINICAL TRIAL IN CHINA.DIAMEDICA -HAS POTENTIAL TO RECEIVE $27.5 MILLION IN DEVELOPMENT, SALES RELATED MILESTONES,HIGH SINGLE & LOW DOUBLE-DIGIT ROYALTIES ON NET SALES OF DM199.  Full Article

China's United Family Healthcare clinches $1.4 billion deal to list in New York

NEW YORK Chinese hospital operator United Family Healthcare will list on the New York Stock Exchange through its $1.4 billion sale to New Frontier Corp , a publicly traded special purpose acquisition vehicle, the companies said on Tuesday.